GPR40 (FFAR1) - Combined Gs and Gq signaling invitro is associated with robust incretin secretagogue action ex vivo and in vivo

Molecular Metabolism

Volumn 4, Issue 1, 2015, Pages 3-14

  Hauge, Maria ^a,b   Vestmar, Marie A ^a,b   Husted, Anna S ^a   Ekberg, Jeppe P ^a   Wright, Michael J ^c   Di Salvo, Jerry ^c   Weinglass, Adam B ^c   Engelstoft, Maja S ^a   Madsen, Andreas N ^a   Lückmann, Michael ^a   Miller, Michael W ^c   Trujillo, Maria E ^c   Frimurer, Thomas M ^a   Holst, Birgitte ^a,b   Howard, Andrew D ^c   Schwartz, Thue W ^a,b  

^a Capital Region   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ago allosteric agonist; Biased signaling; G protein coupled receptor; Glucagon like peptide 1 (GLP 1); Long chain fatty acids (LCFAs)

Indexed keywords

AM 1638; AM 5262; AM 8182; AM 837; CYCLIC AMP; DOCOSAHEXAENOIC ACID; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INOSITOL 1,4,5 TRISPHOSPHATE; LINOLENIC ACID; MK 2305; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; BINDING SITE; CELL CULTURE; CONTROLLED STUDY; CRYPT CELL; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 84920736359     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.10.002     Document Type: Article

References (51)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiological Reviews 2007, 87:1409-1439.
2. Irwin N., Flatt P.R. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Current Opinion in Pharmacology 2013, 13:989-995.
3. Engelstoft M.S., Egerod K.L., Lund M.L., Schwartz T.W. Enteroendocrine cell types revisited. Current Opinion in Pharmacology 2013, 13:912-921.
4. Bohorquez D.V., Liddle R.A. Axon-like basal processes in enteroendocrine cells: characteristics and potential targets. Clinical and Translational Science 2011, 4:387-391.
5. Schmidt J.B., Gregersen N.T., Pedersen S.D., Arentoft J.L., Ritz C., Schwartz T.W., et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. American Journal of Physiology. Endocrinology and Metabolism 2014, 306:E1248-E1256.
6. Engelstoft M.S., Egerod K.L., Holst B., Schwartz T.W. Agut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metabolism 2008, 8:447-449.
7. Reimann F., Tolhurst G., Gribble F.M. G-protein-coupled receptors in intestinal chemosensation. Cell Metabolism 2012, 15:421-431.
8. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. Journal of Endocrinology 1993, 138:159-166.
9. Hansen H.S., Rosenkilde M.M., Holst J.J., Schwartz T.W. GPR119 as a fat sensor. Trends in Pharmacological Sciences 2012, 33:374-381.
10. Itoh Y., Kawamata Y., Harada M., Kobayashi M., Fujii R., Fukusumi S., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
11. Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K., Eilert M.M., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. Journal of Biological chemistry 2003, 278:11303-11311.
12. Kotarsky K., Nilsson N.E., Flodgren E., Owman C., Olde B. Ahuman cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochemical and Biophysical Research Communications 2003, 301:406-410.
13. Briscoe C.P., Peat A.J., McKeown S.C., Corbett D.F., Goetz A.S., Littleton T.R., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. British Journal of Pharmacology 2006, 148:619-628.
14. Paulsen S.J., Larsen L.K., Hansen G., Chelur S., Larsen P.J., Vrang N. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion. PLoS One 2014, 9:e88227.
15. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metabolism 2006, 3:167-175.
16. Jones R.M., Leonard J.N., Buzard D.J., Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opinion on Therapeutic Patents 2009, 19:1339-1359.
17. Mancini A.D., Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?. Trends in Endocrinology & Metabolism 2013, 24:398-407.
18. Steneberg P., Rubins N., Bartoov-Shifman R., Walker M.D., Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metabolism 2005, 1:245-258.
19. Latour M.G., Alquier T., Oseid E., Tremblay C., Jetton T.L., Luo J., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion invivo. Diabetes 2007, 56:1087-1094.
20. Wagner R., Kaiser G., Gerst F., Christiansen E., Due-Hansen M.E., Grundmann M., et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 2013, 62:2106-2111.
21. Christiansen E., Hansen S.V., Urban C., Hudson B.D., Wargent E.T., Grundmann M., et al. Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Medicinal Chemistry Letters 2013, 4:441-445.
22. Edfalk S., Steneberg P., Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
23. Reimann F., Habib A.M., Tolhurst G., Parker H.E., Rogers G.J., Gribble F.M. Glucose sensing in L cells: a primary cell study. Cell Metabolism 2008, 8:532-539.
24. Burant C.F., Viswanathan P., Marcinak J., Cao C., Vakilynejad M., Xie B., et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:1403-1411.
25. Leifke E., Naik H., Wu J., Viswanathan P., Demanno D., Kipnes M., et al. Amultiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clinical Pharmacology & Therapeutics 2012, 92:29-39.
26. Yabuki C., Komatsu H., Tsujihata Y., Maeda R., Ito R., Matsuda-Nagasumi K., et al. Anovel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One 2013, 8:e76280.
27. Lin D.C., Guo Q., Luo J., Zhang J., Nguyen K., Chen M., et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Molecular Pharmacology 2012, 82:843-859.
28. Wang Y., Liu J., Dransfield P.J., Zhu L., Wang Z., Du X., et al. Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. ACS Medicinal Chemistry Letters 2013, 4:551-555.
29. Xiong Y., Swaminath G., Cao Q., Yang L., Guo Q., Salomonis H., et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Molecular and Cellular Endocrinology 2013, 369:119-129.
30. Schwartz T.W., Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?. Trends in Pharmacological Sciences 2007, 28:366-373.
31. Luo J., Swaminath G., Brown S.P., Zhang J., Guo Q., Chen M., et al. Apotent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 2012, 7:e46300.
32. Srivastava A., Yano J., Hirozane Y., Kefala G., Gruswitz F., Snell G., et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 2014, 513:124-127.
33. Negoro N., Sasaki S., Mikami S., Ito M., Suzuki M., Tsujihata Y., et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Medicinal Chemistry Letters 2010, 1:290-294.
34. Brown S.P., Dransfield P.J., Vimolratana M., Jiao X., Zhu L., Pattaropong V., et al. Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist. ACS Medicinal Chemistry Letters 2012, 3:726-730.
35. Brown S.P., Cao Q., Dransfield P.J., Du X., Fu Z., Houze J., et al. Substituted biphenyl GPR40 modulators 2011, US8030354 B2, Amgen Inc.
36. Ge M., Yang L., Zhou C., Lin S., Tang H., Cline E.D., et al. Antidiabetic bicyclic compounds 2006, WO2006083781 A1, Merck and Co. Inc.
37. Neves M.A., Totrov M., Abagyan R. Docking and scoring with ICM: the benchmarking results and strategies for improvement. Journal of Computer-Aided Molecular Design 2012, 26:675-686.
38. Kadamur G., Ross E.M. Mammalian phospholipase C. Annual Review of Physiology 2013, 75:127-154.
39. Seino S., Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiological Reviews 2005, 85:1303-1342.
40. Gloerich M., Bos J.L. Epac: defining a new mechanism for cAMP action. Annual Review of Pharmacology and Toxicology 2010, 50:355-375.
41. Liou A.P., Lu X., Sei Y., Zhao X., Pechhold S., Carrero R.J., et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 2011, 140:903-912.
42. Parker H.E., Habib A.M., Rogers G.J., Gribble F.M., Reimann F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009, 52:289-298.
43. Neubig R.R., Spedding M., Kenakin T., Christopoulos A. International Union of Pharmacology Committee on receptor N, drug C. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacological Reviews 2003, 55:597-606.
44. Christopoulos A., Kenakin T. Gprotein-coupled receptor allosterism and complexing. Pharmacological Reviews 2002, 54:323-374.
45. Christopoulos A., Changeux J.P., Catterall W.A., Fabbro D., Burris T.P., Cidlowski J.A., et al. International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacological Reviews 2014, 66:918-947.
46. Nygaard R., Frimurer T.M., Holst B., Rosenkilde M.M., Schwartz T.W. Ligand binding and micro-switches in 7TM receptor structures. Trends in Pharmacological Sciences 2009, 30:249-259.
47. Kobilka B., Schertler G.F. New G-protein-coupled receptor crystal structures: insights and limitations. Trends in Pharmacological Sciences 2008, 29:79-83.
48. Hanson M.A., Stevens R.C. Discovery of new GPCR biology: one receptor structure at a time. Structure 2009, 17:8-14.
49. Schwartz T.W., Rosenkilde M.M. Is there a 'lock' for all agonist 'keys' in 7TM receptors?. Trends in Pharmacological Sciences 1996, 17:213-216.
50. Wisler J.W., Xiao K., Thomsen A.R.B., Lefkowitz R.J. Recent developments in biased agonism. Current Opinion in Cell Biology 2014, 27:18-24.
51. Reiter E., Ahn S., Shukla A.K., Lefkowitz R.J. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annual Review of Pharmacology and Toxicology 2012, 52:179-197.